Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $36.75, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Price: $21.17, Change: $+0.10, Percent Change: +0.47%
Cirrus Logic (CRUS) reported fiscal Q1 adjusted earnings late Wednesday of $1.84 per diluted share, up from $1.51 a year earlier.Analysts polled by FactSet expected $1.81.Revenue in the three months ended June 27 rose to $459.7 million from $407.3 million a year ago.Four analysts expected $460.3 million.The company expects fiscal Q2 revenue of $510 million to $570 million. Analysts project $570.1 million.Cirrus Logic shares fell 3.4% in after-hours trading.
Tenaris (TS) reported Q2 earnings late Wednesday of $0.95 per American depository share, down from $0.99 a year earlier.Four analysts polled by FactSet expected $0.83.Revenue in the three months ended June 30 fell to $2.97 billion from $3.09 billion a year earlier.Analysts expected $2.93 billion.Tenaris shares fell 5.5% in after-hours trading.
Block (XYZ) reported Q2 adjusted earnings late Wednesday of $1.02 per diluted share, up from $0.62 a year earlier.Analysts polled by FactSet expected $0.87.Revenue in the three months ended June 30 rose to $6.62 billion from $6.05 billion a year earlier.Analysts projected $6.47 billion.Block expects Q3 adjusted diluted EPS of $1.02. Analysts project $1.01.The company increased full-year adjusted EPS guidance to $4.02 from the prior outlook of $3.85. Analysts project $3.90.Block shares fell 1.7% in after-hours trading.